MedLab releases update on Nanabis


MedLab Clinical (ASX: MDC) has released and update on their medicinal cannabis product – Nanabis, which contains a 1:1 ratio of CBD and THC for the treatment of chronic pain.

Nanbis is a side of cheek spray currently in the second stage of a cancer pain trial. In October 2018, Medlab announced successful completion of stage 1 of the trial at Royal North Shore Hospital in Sydney, which is the safety and tolerability phase.

This data has been compared to published data of an approved medicinal cannabis medication listed on the ARTG, showing similar plasma levels of THC and CBD with half the dose, and a faster absorption rate. This indicates that Nanabis is a more effective delivery method of active ingredients than the approved comparison.

Stage 2 will focus on further safety, tolerance and dose escalation.

MedLab also released a number of case studies to demonstrate the effectiveness of Nanabis. These indicated significant improvements in quality of life from reduction in pain and better sleep, and reduction of other medications.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”